Hookipa Pharma: HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented as a late-breaking poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), taking place in Houston, Texas from November 8-10, 2024.The poster will be presented by Alan Ho, MD, PhD, Chief of the Head and Neck Oncology Service at Memorial Sloan Cancer Center (MSKCC), a clinical collaborator of HOOKIPA.Details of the poster presentation are:Abstract Title: Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patientsPresenter: Dr. Alan Ho, MSKCCSession Date: Saturday, November 9, 2024Session Time: 9:00 AM - 8:00 PM CDTLate Breaking Abstract Number: 1480The poster will be available on November 9, 2024 on the HOOKIPA website on the "Scientific Publications" tab of the "Our Science" page.About Eseba-vecEseba-vec (also known as HB-200) is an investigational immunotherapeutic agent being evaluated for HPV16 positive cancers. The first indication for eseba-vec is for the potential treatment of patients with HPV16+ recurrent/metastatic oropharyngeal squamous cell carcinoma (R/M OPSCC) with a PDL1 CPS of 20 or higher, in combination with pembrolizumab, in the first line (1L) setting. Eseba-vec has received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency for the ...Full story available on Benzinga.com